Aurigene Tech Team, Author at Aurigene

April 8, 2022

by Aurigene Tech Team

APRIL 8 – APRIL 13, 2022 American Association for Cancer Research (AACR) Annual Meeting

Presentation Title: AUR103 an oral small molecule CD47 antagonist in combination with azacytidine and bortezomib exhibits potent anti-tumor activity in myeloma and leukemia models in vitro and in vivohttps://www.abstractsonline.com/pp8/#!/10517/presentation/17070 Presentation

Exelixis in-licenses second anti-cancer compound from Aurigene following FDA acceptance of investigational new drug application for phase 1 clinical trial in non-hodgkin’s lymphoma

December 14, 2021

by Aurigene Tech Team

Exelixis in-licenses second anti-cancer compound from Aurigene following FDA acceptance of investigational new drug application for phase 1 clinical trial in non-hodgkin’s lymphoma

– Robust preclinical data support Exelixis’ clinical development of XL114, with phase 1 trial in Non-Hodgkin’s lymphoma expected to begin in the coming months – – Exelixis will make an option exercise

December 7, 2020

by Aurigene Tech Team

Exelixis in-licenses Aurigene’s novel CDK7 inhibitor and files investigational new drug application for phase 1 clinical trial in advanced solid tumors

– Phase 1 clinical trial expected to begin in Q1 2021 – Under the terms of the companies’ agreement, Exelixis will make an option exercise payment of $12 million to

October 9, 2020

by Aurigene Tech Team

Exelixis and Aurigene Announce That Promising Preclinical Data to Be Presented at the ENA Symposium Support the Clinical Development of a Novel CDK7 Inhibitor

Exelixis and Aurigene Announce That Promising Preclinical Data to Be Presented at the ENA Symposium Support the Clinical Development of a Novel CDK7 Inhibitor – Detailed characterization of an oral

February 19, 2020

by Aurigene Tech Team

Aurigene Announces First Patient Dosed with AUR101 in Phase II Study in Patients with Moderate to Severe Psoriasis

PRESS RELEASE Aurigene Announces First Patient Dosed with AUR101 in Phase II Study in Patients with Moderate to Severe Psoriasis Bangalore, February 17, 2020 — Aurigene, a development stage

February 7, 2020

by Aurigene Tech Team

Curis and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170

PRESS RELEASE Curis and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170 – Aurigene to fund and conduct a Phase 2b/3 randomized study of CA-170 in

July 31, 2019

by Aurigene Tech Team

Exelixis and Aurigene Enter Into Exclusive Collaboration, Option and License Agreement to Discover and Develop Novel Therapies for Cancer

ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into an exclusive collaboration, option and license agreement with Aurigene Discovery Technologies Limited (Aurigene), the India-based discovery biotechnology

July 10, 2018

by Aurigene Tech Team

Aurigene Announces First in Human Dosing with RoRγt inverse agonist AUR-101

– Phase 1 data from the study expected to be available by December 2018 Aurigene, a biotechnology company focused on discovering and developing drugs for oncology and inflammatory disorders,

April 11, 2018

by Aurigene Tech Team

AACR 2018 Annual Meeting

Aurigene will be presenting multiple posters at the annual American Association for Cancer Research (AACR) Conference scheduled to be held in Chicago, Illinois from April 14-18 More information about the

March 8, 2018

by Aurigene Tech Team

Aurigene and its Partner Curis Announce the dosing of CA-170 in Phase II India trial

The Phase 2 trial is the result of the initial safety data and preliminary evidence of clinical benefit observed in the trial. Aurigene Discovery Technologies Limited, a wholly owned subsidiary